A team of researchers at Roswell Park , led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer. Their findings, newly published in the journal Oncogene, suggest that a set of processes known as the mitochondrial unfolded protein response, could be an Achilles’ heel for this often-deadly cancer type, and may point the way to a new treatment approach.
Governor Kathy Hochul today celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo. The $98 million facility will create new jobs, help to support the research and development of life-saving cell and gene therapies at Roswell, significantly grow its well-established research capabilities, and establish Roswell as one of the premier cell therapy discovery and development institutions in the nation. The expansion also realizes Governor Hochul’s 2023 State of the State commitment to bolster the state’s leadership in the fast-growing CGT sector through establishment of an Upstate cell and gene therapy hub to catalyze its growth in western NY. The GEM facility meets U.S. FDA Good Manufacturing Practice standards for manufacture of clinical cell therapy products, positioning the Roswell Park team to be a multifaceted resource for patients, care teams
A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates — FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center’s first Physician in Chief — and the slate of experts appointed to tackle the most pressing opportunities and challenges related to cancer treatment, outcomes and delivery of care.
A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen the effects of immunotherapy and improve recurrence-free survival in people with lung cancer who are overweight or obese, according to a recently published article in the Journal of the National Cancer Institute.
Roswell Park, in partnership with the University at Buffalo (UB) School of Nursing, has received a five-year, $2.11 million Institutional Clinical Scientist Awards (K12) grant from the National Cancer Institute to establish a training program for nurse-scientists focused around clinical translational research
Roswell Park experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology (ASH), to be held December 7-10 in San Diego, California.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
The Roswell Park team has developed a new method to measure mutation loads across species, revealing the role of the "dark genome" — ancient, virus-like genes that affect cellular function. The findings support further exploration of antiviral drugs as potential tools to target the dark genome in controlling cancer.
Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children’s Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma.
The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
Open Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals configuration options Historically, some patients with blood cancers have been less likely than others to receive stem cell transplant, also known as bone marrow transplant.
A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the disease, a new study led by Roswell Park Chief of Clinical Genomics Kenan Onel, MD, PhD, reveals.
During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment.
A three-year, $689,000 grant from the Bristol Myers Squibb Foundation will enable teams from Roswell Park Comprehensive Cancer Center and the University of New Mexico to collaborate on health navigation services serving the people of the Pueblo Nations.
RSS